# In Situ Analyses of Placental Inflammatory Response to SARS-CoV-2 Infection in Cases of Mother–Fetus Vertical Transmission

**Authors:** Denise Morotti, Silvia Tabano, Gabriella Gaudioso, Tatjana Radaelli, Giorgio Alberto Croci, Nicola Bianchi, Giulia Ghirardi, Andrea Gianatti, Luisa Patanè, Valeria Poletti de Chaurand, David A. Schwartz, Mohamed A. A. A. Hagazi, Fabio Grizzi

PMC · DOI: 10.3390/ijms25168825 · 2024-08-13

## TL;DR

This study explores how SARS-CoV-2 affects placental inflammation and gene expression in cases of mother-to-fetus transmission.

## Contribution

The study provides new insights into placental gene expression and inflammatory responses during SARS-CoV-2 vertical transmission.

## Key findings

- Transcriptomic analysis identified 305 genes with significant expression differences in infected placentae.
- Up-regulated genes suggest a role in inflammatory responses to SARS-CoV-2, including CCL20, C3, and immune-related genes.
- RNAscope® analysis showed higher fetal-side coverage of SARS-CoV-2 and certain interleukins compared to the maternal side.

## Abstract

It has been shown that vertical transmission of the SARS-CoV-2 strain is relatively rare, and there is still limited information on the specific impact of maternal SARS-CoV-2 infection on vertical transmission. The current study focuses on a transcriptomics analysis aimed at examining differences in gene expression between placentas from mother–newborn pairs affected by COVID-19 and those from unaffected controls. Additionally, it investigates the in situ expression of molecules involved in placental inflammation. The Papa Giovanni XXIII Hospital in Bergamo, Italy, has recorded three instances of intrauterine transmission of SARS-CoV-2. The first two cases occurred early in the pandemic and involved pregnant women in their third trimester who were diagnosed with SARS-CoV-2. The third case involved an asymptomatic woman in her second trimester with a twin pregnancy, who unfortunately delivered two stillborn fetuses due to the premature rupture of membranes. Transcriptomic analysis revealed significant differences in gene expression between the placentae of COVID-19-affected mother/newborn pairs and two matched controls. The infected and control placentae were matched for gestational age. According to the Benjamani–Hochberg method, 305 genes met the criterion of an adjusted p-value of less than 0.05, and 219 genes met the criterion of less than 0.01. Up-regulated genes involved in cell signaling (e.g., CCL20, C3, MARCO) and immune response (e.g., LILRA3, CXCL10, CD48, CD86, IL1RN, IL-18R1) suggest their potential role in the inflammatory response to SARS-CoV-2. RNAscope® technology, coupled with image analysis, was utilized to quantify the surface area covered by SARS-CoV-2, ACE2, IL-1β, IL-6, IL-8, IL-10, and TNF-α on both the maternal and fetal sides of the placenta. A non-statistically significant gradient for SARS-CoV-2 was observed, with a higher surface coverage on the fetal side (2.42 ± 3.71%) compared to the maternal side (0.74 ± 1.19%) of the placenta. Although not statistically significant, the surface area covered by ACE2 mRNA was higher on the maternal side (0.02 ± 0.04%) compared to the fetal side (0.01 ± 0.01%) of the placenta. IL-6 and IL-8 were more prevalent on the fetal side (0.03 ± 0.04% and 0.06 ± 0.08%, respectively) compared to the maternal side (0.02 ± 0.01% and 0.02 ± 0.02%, respectively). The mean surface areas of IL-1β and IL-10 were found to be equal on both the fetal (0.04 ± 0.04% and 0.01 ± 0.01%, respectively) and maternal sides of the placenta (0.04 ± 0.05% and 0.01 ± 0.01%, respectively). The mean surface area of TNF-α was found to be equal on both the fetal and maternal sides of the placenta (0.02 ± 0.02% and 0.02 ± 0.02%, respectively). On the maternal side, ACE-2 and all examined interleukins, but not TNF-α, exhibited an inverse mRNA amount compared to SARS-CoV-2. On the fetal side, ACE-2, IL-6 and IL-8 were inversely correlated with SARS-CoV-2 (r = −0.3, r = −0.1 and r = −0.4, respectively), while IL-1β and IL-10 showed positive correlations (r = 0.9, p = 0.005 and r = 0.5, respectively). TNF-α exhibited a positive correlation with SARS-CoV-2 on both maternal (r = 0.4) and fetal sides (r = 0.9) of the placenta. Further research is needed to evaluate the correlation between cell signaling and immune response genes in the placenta and the vertical transmission of SARS-CoV-2. Nonetheless, the current study extends our comprehension of the molecular and immunological factors involved in SARS-CoV-2 placental infection underlying maternal–fetal transmission.

## Linked entities

- **Genes:** CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364], C3 (complement C3) [NCBI Gene 718], MARCO (macrophage receptor with collagenous structure) [NCBI Gene 8685], LILRA3 (leukocyte immunoglobulin like receptor A3) [NCBI Gene 11026], CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627], CD48 (CD48 molecule) [NCBI Gene 962], CD86 (CD86 molecule) [NCBI Gene 942], IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557], IL18R1 (interleukin 18 receptor 1) [NCBI Gene 8809], ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272], IL6 (interleukin 6) [NCBI Gene 3569], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576], IL1B (interleukin 1 beta) [NCBI Gene 3553], IL10 (interleukin 10) [NCBI Gene 3586], TNF (tumor necrosis factor) [NCBI Gene 7124]
- **Diseases:** SARS-CoV-2 (MONDO:0100096), COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CD48 (CD48 molecule) [NCBI Gene 962] {aka BCM1, BLAST, BLAST1, MEM-102, SLAMF2, hCD48}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MARCO (macrophage receptor with collagenous structure) [NCBI Gene 8685] {aka SCARA2, SR-A6}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, IL18R1 (interleukin 18 receptor 1) [NCBI Gene 8809] {aka CD218a, CDw218a, IL-18R, IL-18R-alpha, IL-18Ralpha, IL-1Rrp}, LILRA3 (leukocyte immunoglobulin like receptor A3) [NCBI Gene 11026] {aka CD85E, HM31, HM43, ILT-6, ILT6, LIR-4}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}
- **Diseases:** premature rupture of membranes (MESH:D005322), Inflammatory (MESH:D007249), COVID-19 (MESH:D000086382), placental infection (MESH:D010922)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11355016/full.md

---
Source: https://tomesphere.com/paper/PMC11355016